Singapore, August 7, 2009 - Zecotek Photonics Inc. (TSX-V: ZMS; Frankfurt: W1I.F), a developer of leading-edge photonics technologies for medical, industrial and scientific markets, today announced that it has retained CHF Investor Relations (Cavalcanti Hume Funfer Inc.), (“CHF”), an investor relations firm whose management team’s combined experience accounts for a full century working in brokerage, trading, financial analysis, and investment sales.

“Having worked with CHF two years ago, we are very comfortable with their approach to audience-building and investor relations,” said Dr. A.F. Zerrouk, Chairman, President, and CEO of Zecotek.  “The accomplishments Zecotek has made since then indicate to us that now is the time to actively re-engage with investors and the financial community at large.”

Effective immediately the investor relations services agreement, which includes market-making services, is for a fixed term of twelve months. In the absence of termination notice, services may continue past the twelve months, on an open-ended basis allowing for cancellation upon three months’ termination notice by either party. The agreement compensates CHF with monthly fees starting initially at C$5,000 for the first six months of service, and up to C$7,500 per month thereafter.

About CHF Investor Relations
CHF acts as an outsourced, low-cost equivalent to an internal investor relations department. CHF serves an international portfolio of TSX / Venture-listed companies, and others that may seek to list on North American Exchanges, that operate in a broad range of industries including high-tech, industrial and business solutions and products, mining exploration and producers, oil & gas, niche financial products, and "green" companies. CHF's head office is in Toronto, with another Canadian office in Calgary; as well as branch offices in New York, USA; São Paulo, Brazil; and Shanghai, China.

About Zecotek
Zecotek Photonics Inc. (TSX-V: ZMS; Frankfurt: W1I) is a photonics technology company developing leading-edge products: crystals, photo detectors, lasers, imaging and 3D display technologies, for medical, biotech, industrial, nanotech and atomic/molecular science applications. Founded in 2003, the company has three distinct operating divisions: Laser Systems, Imaging Systems and 3D Display Systems and labs located in Canada, the United States, Singapore, Malaysia and Russia. Zecotek commercializes its novel, patented and patent-pending photonic technologies directly and through strategic alliances and joint ventures with multinational OEMs, distributors and other industry leaders.  For more information, please visit www.zecotek.com.

This press release may contain forward-looking statements that are based on management’s expectations, estimates, projections and assumptions. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what may have been stated.

CHF Investor Relations
Christopher Haldane, Account Manager
T: (416) 868-1079 x237
chris@chfir.com

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release. If you would like to receive news from Zecotek in the future please visit the corporate website at www.zecotek.com.